We thank Dr Pischon and colleagues for their interest in our work. 1 We have reported the largest single prospective populationbased study of adiponectin levels and coronary heart disease thus far, reinforced by a meta-analysis of 6 previous studies totaling 1313 incident cases. 1 Overall, the adjusted risk ratio for coronary heart disease was 0.84 (95% CI: 0.70 to 1.01) in a comparison of individuals in the top third with those in the bottom third of baseline adiponectin concentrations, and there was no evidence of heterogeneity among the 7 reports ( 2 ϭ8.4; Pϭ0.21; I 2 ϭ29% [95% CI: 0% to 69%]). We analyzed the new data using different cut points, such as comparisons of extreme fifths (adjusted odds ratio: 1.12; 95% CI: 0.75 to 1.66) and per 50% increase in log e adiponectin levels (adjusted odds ratio: 1.02; 95% CI: 0.93 to 1.12). Although the available evidence suggests that adiponectin levels are less strongly associated with coronary heart disease risk than was previously suspected, we have stated that further data are needed.
